There is no obsession with the share price. Just as there wasn’t an obsession in 2015 all the way to 36c. What has changed is that in 2015 to 2017, the commentary was all about the science. Beyond successful ASTM testing, the question of marketability came because of a lack of market acceptance, ie, very low sales. We’ve since learnt that HC and P had to be developed. The share price has accurately reflected the concerns raised in the Questions sent to GS and not answered. Along with subsequent news of developing a lower cost version (HC) and a P variant and very low sales, the share price has mostly confirmed the answer. Since the Questions were sent, the share price has gone from 22c to 7c.
Cheers
Add to My Watchlist
What is My Watchlist?
